ESR1 and neoplasm: Neoadjuvant chemotherapy was initially reserved for surgically inoperable patients, extended to include larger tumours (>5 cm in 2010), and by 2016 encompassing most estrogen receptor (ER)-negative and/or human epidermal growth factor receptor 2 (HER2)-positive tumours.